Gujarat Themis Biosyn has agreed to acquire 13 anti-infective branded generics from Sanofi for €158 million. This deal is aimed at expanding GTBL's global reach and is expected to be finalized by December 2026, subject to regulatory approvals.

GTBL has secured a €158M acquisition of Sanofi's pharmaceutical portfolio, expanding its reach in the market, particularly in anti-infective treatments. This move strengthens GTBL's position by increasing their offerings and regulatory influence.